BBIO stock forecast
Our latest prediction for BridgeBio Pharma, Inc.'s stock price was made on the Aug. 4, 2020 when the stock price was at 27.40$.
In the short term (2weeks), BBIO's stock price should underperform the market by -2.37%. During that period the price should oscillate between -10.28% and +9.49%.
In the medium term (3months), BBIO's stock price should underperform the market by -7.38%. During that period the price should oscillate between -39.33% and +22.97%.Get email alerts
Create a solid portfolio with BBIO
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
At the moment the company generates 41M USD in revenues.
On its last earning announcement, the company reported a loss of -2.92$ per share.
The book value per share is 2.09$
Three months stock forecastAug. 4, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|